Company News: Medivation, Hacker Group and HealthHG

Share this article:
San Francisco-based biotech Medivation said it will cut 23 positions – a fifth of its staff – as part of a cost-cutting exercise in the wake of the failure of Alzheimer's drug candidate dimebon, which the firm was partnering with Pfizer on. Medivation will continue to work on Alzheimer's and Huntington disease applications for dimebon and on its MDV3100 for prostate cancer.

Hacker Group, a Seattle-based digital and direct marketing shop, announced that it is launching a health insurance marketing practice, dubbed HealthHG. The practice will be led by VP account services Jill Kaufman and chief strategist Tom Reid. Clients include Highmark Blue Shield, EmblemHealth and Blue Cross Blue Shield of Alabama.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Imbruvica lassoes CLL indication

The FDA slapped a Breakthrough Therapy label on the CLL indication pursuit in February.

FDA asks social media "how'm I doin?"

The FDA's Center for Drug Evaluation and Research's Office of Communications wants a system that will help assess its messaging reach across the interwebs and its many forums.

Reckitt Benckiser wants out of pharma

The company plans to spin off its pharmaceutical unit.